PMID- 25746818
OWN - NLM
STAT- MEDLINE
DCOM- 20160126
LR  - 20160303
IS  - 2374-4243 (Electronic)
IS  - 2374-4243 (Linking)
VI  - 47
IP  - 7
DP  - 2015 Jul
TI  - Rapid human immunodeficiency virus disease progression is associated with human 
      leukocyte antigen-B homozygocity and human leukocyte antigen-B51 in a cohort from 
      Manitoba, Canada.
PG  - 447-52
LID - 10.3109/00365548.2015.1007474 [doi]
AB  - BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) infection is associated 
      with variable rates of disease progression, influenced by the quality of CD8 
      T-lymphocyte response, which is determined by human leukocyte antigen (HLA) I 
      alleles. Some individuals progress slowly and maintain viral control, while at 
      the opposite end of the spectrum some individuals endure a faster progression 
      with rapid CD4 decline. We sought to determine the role of HLA-B allele frequency 
      on rapid HIV disease progression. It was hypothesized that rapid progression is 
      associated with the presence of high allele frequency of HLA-B35 and HLA-B 
      homozygocity. METHODS: This retrospective cohort study was conducted in the 
      Manitoba HIV Program, Health Sciences Centre, a tertiary care facility in 
      Winnipeg, Manitoba, Canada. We defined a set of new criteria to describe a subset 
      of individuals with the most rapid HIV disease progression, and collected 
      demographic, clinical, laboratory (CD4 count, viral load) and HLA data on a 
      subset of 20 individuals meeting these criteria. RESULTS: Among those individuals 
      who display extreme rapid progression, an overrepresentation of Aboriginal 
      ethnicities, high frequencies of HLA-B35 and significantly higher rates of 
      HLA-B51, as well as a very high rate of homozygocity for HLA-B alleles, were 
      observed. CONCLUSIONS: Individuals with the most rapid disease progression have 
      higher rates of HLA-B homozygocity, HLA-B51 alleles and higher viral loads than 
      those with normal progression rates. This group, at the extreme end of the 
      spectrum of progression, should be targeted for early treatment.
FAU - Keynan, Yoav
AU  - Keynan Y
AD  - From the 1 Manitoba HIV Program , Winnipeg, MB , Canada.
FAU - Becker, Marissa
AU  - Becker M
FAU - Rueda, Zulma
AU  - Rueda Z
FAU - Bresler, Kim
AU  - Bresler K
FAU - Kasper, Ken
AU  - Kasper K
LA  - eng
GR  - CTNPT 004/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150308
PL  - England
TA  - Infect Dis (Lond)
JT  - Infectious diseases (London, England)
JID - 101650235
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B35 Antigen)
RN  - 0 (HLA-B51 Antigen)
SB  - IM
MH  - CD4 Lymphocyte Count
MH  - Disease Progression
MH  - Gene Frequency
MH  - HIV Infections/ethnology/*genetics/*immunology/virology
MH  - HLA-B Antigens/*genetics
MH  - HLA-B35 Antigen
MH  - HLA-B51 Antigen/genetics/*metabolism
MH  - *Homozygote
MH  - Humans
MH  - Manitoba/ethnology
MH  - Retrospective Studies
MH  - Viral Load
OTO - NOTNLM
OT  - CD4 decline
OT  - HIV disease progression
OT  - HLA homozygocity
OT  - HLA-B
EDAT- 2015/03/10 06:00
MHDA- 2016/01/27 06:00
CRDT- 2015/03/10 06:00
PHST- 2015/03/10 06:00 [entrez]
PHST- 2015/03/10 06:00 [pubmed]
PHST- 2016/01/27 06:00 [medline]
AID - 10.3109/00365548.2015.1007474 [doi]
PST - ppublish
SO  - Infect Dis (Lond). 2015 Jul;47(7):447-52. doi: 10.3109/00365548.2015.1007474. 
      Epub 2015 Mar 8.